Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 7/20 | 0.52 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.44 |
| ▸ | PYGM | P11217 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 2/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | MAX | P61244 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294722 | 0.87 | PYGL (0.42) | PYGLEIF4A1PYGMSMN1; SMN2BRD4 | |
| SCHEMBL8486260 | 0.85 | BRD4 (0.43) | PYGLSMN1; SMN2KDM4EBRD4MERTK | |
| SCHEMBL6296041 | 0.83 | ALDH1A1 (0.43) | PYGLEIF4A1KDM4EBRD4MERTK | |
| SCHEMBL6294975 | 0.81 | PYGL (0.42) | PYGLPYGMSMN1; SMN2BRD4 | |
| SCHEMBL6300791 | 0.80 | MAPT (0.40) | PYGLSMN1; SMN2KDM4EBRD4MERTK | |
| SCHEMBL6295779 | 0.78 | MERTK (0.42) | PYGLEIF4A1BRD4MERTKPTGDR2 | |
| SCHEMBL6294962 | 0.76 | PYGL (0.40) | PYGLSMN1; SMN2 | |
| SCHEMBL6300744 | 0.76 | EPAS1 (0.44) | PYGLKDM4EMERTK | |
| SCHEMBL6294697 | 0.75 | LMNA (0.52) | PYGLSMN1; SMN2KDM4EMERTKPTGDR2 | |
| SCHEMBL6300671 | 0.75 | PYGL (0.38) | PYGLSMN1; SMN2KDM4EBRD4MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916837-B2 | Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them | EISAI CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1312602-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | Eisai Co., Ltd. (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | F2, SERPINC1, F12 | PYGL 1434/4885EIF4A1 1052/4885PYGM 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.